Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.

Publication date: Mar 12, 2024

Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial. Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused by SARS-CoV-2 and plasma-soluble urokinase plasminogen activator receptor levels of ≥ 6 ng/ml in the SAVE-MORE trial (NCT04680949) were characterized at baseline and days 4 and 7 of treatment using a previously defined 33-messenger RNA classifier to assign an immunological endotype in blood. Endpoints were changes in endotypes and progression to severe respiratory failure (SRF) associated with anakinra treatment. At baseline, 23. 2% of 393 patients were designated as inflammopathic, 41. 1% as adaptive, and 35. 7% as coagulopathic. Only 23. 9% were designated as the same endotype at days 4 and 7 compared to baseline, while all other patients transitioned between endotypes. Anakinra-treated patients were more likely to remain in the adaptive endotype during 7-day treatment (24. 4% vs. 9. 9%; p 

Concepts Keywords
Improved Anakinra
Nct04680949 COVID-19
Pcr Endotypes
Pneumonia Viral sepsis


Type Source Name
disease IDO blood
drug DRUGBANK Anakinra
disease MESH COVID-19
disease MESH pneumonia
disease MESH sepsis
disease MESH respiratory failure

Original Article

(Visited 1 times, 1 visits today)